Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
Products
Automate
Trackers
Innovation Services
About Index
Index
By TNW
Log in
Register
Arvinas
3122
Arvinas
Technology
Biotechnology
Health Care
Medical
Therapeutics
We are developing firstinclass protein degradation therapeutics to degrade & destroy diseasecausing proteins via the body's own protein disposal system.
Suggest edits
Raised
$175M
Follow us
Companies in the same industry
Advanced BioDesign
Cardiff Oncology
Nine Square Therapeutics
Curi Bio
Capricor Therapeutics
eTheRNA Immunotherapies
Clearside BioMedical, Inc.
Mersana Therapeutics
Brainvectis
Immunic AG
Alexa global traffic share
Twitter followers
Overview
Funding
2
People
Add info
Latest funding
$120,000,000
IPO - 2018
$55,000,000
Venture capital (Series C) - 2018
Canaan Partners
RA Capital Management
New Leaf Venture Partners
+6
Team Size
1–10
Employees
I work here
Location
United States
Headquarters
Explore United States
Xconomy
Bayer and Arvinas Join Forces in $115M Pharma & Ag Research Alliance
$120,000,000
IPO
PE HUB
VC-backed Arvinas goes public
$55,000,000
Venture capital (Series C)
Venture Funding News
,
PE HUB
Arvinas Completes $55M Series C
